Multiple Myeloma and EasyM Resource Centre.
Featured
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Iain Rogers2025-02-28T09:22:26-05:00August 3rd, 2024|Case Studies|
Publications, Posters & Case Studies
Iain Rogers2025-06-16T10:34:11-04:00
Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
Iain Rogers2025-06-16T10:34:11-04:00March 21st, 2024|Publication|
Iain Rogers2025-02-19T15:32:29-05:00
Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias
Iain Rogers2025-02-19T15:32:29-05:00December 17th, 2023|Poster|
Iain Rogers2025-02-19T14:30:19-05:00
Measurable Residual Disease Status By Clonotypic Mass Spectrometry with EasyM Assay Predicts Outcomes Following AHCT in Multiple Myeloma
Iain Rogers2025-02-19T14:30:19-05:00December 15th, 2023|Poster|